Predictive, personalized, preventive, participatory (P4) cancer medicine
- PMID:21364692
- DOI: 10.1038/nrclinonc.2010.227
Predictive, personalized, preventive, participatory (P4) cancer medicine
Abstract
Medicine will move from a reactive to a proactive discipline over the next decade--a discipline that is predictive, personalized, preventive and participatory (P4). P4 medicine will be fueled by systems approaches to disease, emerging technologies and analytical tools. There will be two major challenges to achieving P4 medicine--technical and societal barriers--and the societal barriers will prove the most challenging. How do we bring patients, physicians and members of the health-care community into alignment with the enormous opportunities of P4 medicine? In part, this will be done by the creation of new types of strategic partnerships--between patients, large clinical centers, consortia of clinical centers and patient-advocate groups. For some clinical trials it will necessary to recruit very large numbers of patients--and one powerful approach to this challenge is the crowd-sourced recruitment of patients by bringing large clinical centers together with patient-advocate groups.
Comment in
- P5 medicine: a plus for a personalized approach to oncology.Gorini A, Pravettoni G.Gorini A, et al.Nat Rev Clin Oncol. 2011 May 31;8(7):444. doi: 10.1038/nrclinonc.2010.227-c1.Nat Rev Clin Oncol. 2011.PMID:21629214No abstract available.
- P4 medicine or O4 medicine? The perils of population wide, asymptomatic disease screening.Fiala C, Diamandis EP.Fiala C, et al.Clin Biochem. 2020 Mar;77:62. doi: 10.1016/j.clinbiochem.2020.01.002. Epub 2020 Jan 16.Clin Biochem. 2020.PMID:31954691No abstract available.
Similar articles
- A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory.Hood L, Flores M.Hood L, et al.N Biotechnol. 2012 Sep 15;29(6):613-24. doi: 10.1016/j.nbt.2012.03.004. Epub 2012 Mar 18.N Biotechnol. 2012.PMID:22450380
- Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine.Tian Q, Price ND, Hood L.Tian Q, et al.J Intern Med. 2012 Feb;271(2):111-21. doi: 10.1111/j.1365-2796.2011.02498.x.J Intern Med. 2012.PMID:22142401Free PMC article.Review.
- Pharmacomicrobiomics-Guided Precision Oncology: A New Frontier of P4 (Predictive, Personalized, Preventive, and Participatory) Medicine and Microbiome-Based Therapeutics.Arga KY, Attia H, Aziz RK.Arga KY, et al.OMICS. 2024 Jan;28(1):5-7. doi: 10.1089/omi.2023.0254. Epub 2024 Jan 8.OMICS. 2024.PMID:38190279
- Infection systems biology: from reactive to proactive (P4) medicine.Bengoechea JA.Bengoechea JA.Int Microbiol. 2012 Jun;15(2):55-60. doi: 10.2436/20.1501.01.158.Int Microbiol. 2012.PMID:22847266Review.
- Revolutionizing medicine in the 21st century through systems approaches.Hood L, Balling R, Auffray C.Hood L, et al.Biotechnol J. 2012 Aug;7(8):992-1001. doi: 10.1002/biot.201100306. Epub 2012 Jul 20.Biotechnol J. 2012.PMID:22815171Free PMC article.
Cited by
- Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response.Wu M, Zhang Y, Zhang Y, Liu Y, Wu M, Ye Z.Wu M, et al.Radiol Imaging Cancer. 2019 Nov 29;1(2):e190031. doi: 10.1148/rycan.2019190031. eCollection 2019 Nov.Radiol Imaging Cancer. 2019.PMID:33778682Free PMC article.Review.
- A Critical Analysis of the FDA's Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity.Niazi SK.Niazi SK.Pharmaceuticals (Basel). 2023 Nov 2;16(11):1556. doi: 10.3390/ph16111556.Pharmaceuticals (Basel). 2023.PMID:38004421Free PMC article.Review.
- Personalization: a new political arithmetic?Day S, Lury C, Ward H.Day S, et al.Distinktion. 2023 Jan 4;24(2):167-194. doi: 10.1080/1600910X.2022.2098352. eCollection 2023.Distinktion. 2023.PMID:38013839Free PMC article.
- From P0 to P6 medicine, a model of highly participatory, narrative, interactive, and "augmented" medicine: some considerations on Salvatore Iaconesi's clinical story.Bragazzi NL.Bragazzi NL.Patient Prefer Adherence. 2013 Apr 24;7:353-9. doi: 10.2147/PPA.S38578. Print 2013.Patient Prefer Adherence. 2013.PMID:23650443Free PMC article.
- Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area.Li A, Meyre D.Li A, et al.Curr Psychiatry Rev. 2014 May;10(2):118-132. doi: 10.2174/1573400510666140630170549.Curr Psychiatry Rev. 2014.PMID:25598768Free PMC article.
References
Publication types
MeSH terms
Related information
LinkOut - more resources
Full Text Sources